Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems

TH Baryakova, BH Pogostin, R Langer… - Nature Reviews Drug …, 2023 - nature.com
Poor medication adherence is a pervasive issue with considerable health and
socioeconomic consequences. Although the underlying reasons are generally understood …

Tuberculosis drug discovery: challenges and new horizons

GFS Fernandes, AM Thompson… - Journal of Medicinal …, 2022 - ACS Publications
Over the past 2000 years, tuberculosis (TB) has claimed more lives than any other infectious
disease. In 2020 alone, TB was responsible for 1.5 million deaths worldwide, comparable to …

Drug resistant Tuberculosis: A review

JL Khawbung, D Nath, S Chakraborty - … immunology, microbiology and …, 2021 - Elsevier
Tuberculosis (TB) was announced as a global emergency in 1993. There was an alarming
counter attack of TB worldwide. However, when it was known that TB can be cured …

Biological activity of oxadiazole and thiadiazole derivatives

UA Atmaram, SM Roopan - Applied Microbiology and Biotechnology, 2022 - Springer
The 5-membered oxadiazole and thiadiazole scaffolds are the most privileged and well-
known heterocycles, being a common and essential feature of a variety of natural products …

[HTML][HTML] New agents for the treatment of drug-resistant Mycobacterium tuberculosis

DT Hoagland, J Liu, RB Lee, RE Lee - Advanced drug delivery reviews, 2016 - Elsevier
Inadequate dosing and incomplete treatment regimens, coupled with the ability of the
tuberculosis bacilli to cause latent infections that are tolerant of currently used drugs, have …

[HTML][HTML] Tuberculosis 2015: burden, challenges and strategy for control and elimination

M Raviglione, G Sulis - Infectious disease reports, 2016 - ncbi.nlm.nih.gov
Tuberculosis (TB) is a leading cause of morbidity and mortality worldwide, accounting for
about 9.6 million new cases and 1.5 million deaths annually. The poorest and socially …

Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis

MB Harbut, C Vilchèze, X Luo… - Proceedings of the …, 2015 - National Acad Sciences
Infections caused by antibiotic-resistant bacteria are a rising public health threat and make
the identification of new antibiotics a priority. From a cell-based screen for bactericidal …

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b …

R Dawson, AH Diacon, D Everitt, C van Niekerk… - The Lancet, 2015 - thelancet.com
Background New antituberculosis regimens are urgently needed to shorten tuberculosis
treatment. Following on from favourable assessment in a 2 week study, we investigated a …

Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid

PJ Gómez-González, J Perdigao, P Gomes… - Scientific reports, 2021 - nature.com
Tuberculosis (TB), caused by Mycobacterium tuberculosis, is one of the deadliest infectious
diseases worldwide. Multidrug and extensively drug-resistant strains are making disease …

Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery

M Datta, LE Via, WS Kamoun, C Liu… - Proceedings of the …, 2015 - National Acad Sciences
Tuberculosis (TB) causes almost 2 million deaths annually, and an increasing number of
patients are resistant to existing therapies. Patients who have TB require lengthy …